LH News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$25.78B

Volume

494.17K

Next Earnings

October 28th

Mkt Cap

$25.79B

Volume

494.17K

Next Earnings

October 28th

Chart Financials Earnings News About Dividends Insider Filings

OPKO Health to Sell Select BioReference Assets to Labcorp for $722MOPKO Health announced an agreement to sell select BioReference assets to Labcorp for $722 million in cash plus up to $150 million in earnouts. The deal includes the 4Kscore Test, specialty testing operations, and over 80 patient service centers. OPKO aims to focus on its biopharmaceutical business, while Labcorp expects $250 million in first-year revenue from the acquisition. OPK stock rose 17.5% following the announcement.Zacks Investment Research · Oct 16, 2026

PACS Group, Inc. (PACS) Surges 6.2%: Is This an Indication of Further Gains?PACS Group shares jumped 6.2% to $47.75 on investor optimism ahead of Q3 2026 earnings release. The company is expected to report 75% earnings growth and 8.1% revenue growth. However, with unchanged consensus EPS estimates over the past 30 days, analysts caution that the stock may lack momentum for sustained gains without positive estimate revisions.Zacks Investment Research · Oct 16, 2026

Global Decentralized Clinical Trials Market Size, Trends, and Forecast, 2025-2030 | AI, Wearables, and Cloud-Based Platforms Fuel 13.7% CAGR to $18.8 BillionThe global Decentralized Clinical Trials (DCT) market is valued at $8.8 billion in 2025 and is projected to reach $18.8 billion by 2030, growing at a 13.7% CAGR. Growth is driven by AI integration, wearable technologies, cloud-based platforms, and increased adoption of remote research capabilities across pharmaceutical, biotechnology, and contract research sectors.GlobeNewswire Inc. · Oct 9, 2026

Here's Why Labcorp Holdings (LH) is a Strong Value StockLabcorp Holdings (LH), a leading healthcare diagnostics company, receives a #3 (Hold) rating on the Zacks Rank with a VGM Score of B. The company shows attractive valuation metrics with a forward P/E ratio of 16.84 and has seen three analyst upward earnings revisions in the last 60 days, with the consensus estimate increasing to $18.32 per share for fiscal 2026.Zacks Investment Research · Oct 6, 2026

DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace?Danaher Corporation's Biotechnology segment drove growth with 4% reported sales increase to $1.92 billion in Q2 2026, bolstered by strong China demand and consumables sales. Despite regional headwinds in Western Europe and North America, DHR expects mid-single-digit core growth in 2026. The stock trades at a premium valuation of 24.92X forward P/E versus the industry average of 16.59X and carries a Zacks Rank #3 (Hold).Zacks Investment Research · Sep 30, 2026

Is This the Right Time to Add Labcorp Stock to Your Portfolio?Labcorp Holdings is expanding its specialty testing business in oncology, women's health, autoimmune disease, and neurology through strategic acquisitions and partnerships. The company is leveraging AI and automation to improve margins, with operating margins expanding 70 basis points year-over-year. However, macroeconomic uncertainty, cost inflation, and changing reimbursement policies pose risks to testing volumes and profitability.Zacks Investment Research · Sep 29, 2026

GENFIT Reports First-Half 2026 Financial Results and Provides Corporate UpdateGENFIT reported strong first-half 2026 financial results with €113.8 million in cash, driven by tripling royalty revenues from Ipsen's Iqirvo® (€21.1 million) and a €17 million milestone payment. The company is advancing three Phase 2 clinical trials including nangibotide and nitazoxanide for ACLF, while its NIS™ diagnostic technology achieved Medicare coverage for NASHnext®. Ipsen doubled Iqirvo's peak sales target to €1 billion for PBC, and IQVIA estimates NIS™-based products could exceed $1.5 billion in U.S. peak sales by 2033.GlobeNewswire Inc. · Sep 28, 2026

Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product SegmentsThe global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.GlobeNewswire Inc. · Sep 24, 2026

Why Labcorp Holdings Stock Dropped TodayLabcorp Holdings stock fell 3.3% after the Centers for Medicare & Medicaid Services announced plans to reduce lab testing reimbursement rates by 15% starting next year, with potential additional cuts through 2029. Since CMS accounts for approximately 8% of Labcorp's revenue, a full 15% reduction would decrease annual revenue by 1.2%, with a worst-case scenario of 3.6% reduction if cuts continue through 2029. The stock's decline appears to have already priced in this worst-case scenario.The Motley Fool · Sep 22, 2026

Rare Disease Contract Research Organization (CRO) Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share OutlookThe global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.GlobeNewswire Inc. · Sep 21, 2026

LHLabcorp Holdings Inc.

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any LH yet.

Related Tickers

Earnings

Dividends

Last · Aug 28Quarterly

Amount$0.72

Yield0.91%

Annual$2.88

Mkt Cap

$25.78B

Volume

494.17K

Next Earnings

October 28th